Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 2,486
Change Today 0.00 / 0.00%
Volume 0.0
CGEN On Other Exchanges
As of 10:24 AM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

compugen ltd (CGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - $3,770
52 Week Low
05/17/15 - $2,405
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COMPUGEN LTD (CGEN)

compugen ltd (CGEN) Related Businessweek News

No Related Businessweek News Found

compugen ltd (CGEN) Details

Compugen Ltd., a drug discovery company, engages in the research, development, and commercialization of therapeutic and product candidates primarily in the United States, Europe, and Israel. It primarily focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins to address the unmet needs in the fields of oncology and immunology. The company’s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 for the treatment of a range of diseases including cancer, autoimmune and infectious diseases, blood-related disorders, and others. Its monoclonal antibody therapy product candidates comprise CGEN-15001T, CGEN-15022, CGEN-15049, CGEN-15027, CGEN-15092, and CGEN-15052. The company was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

83 Employees
Last Reported Date: 03/12/15
Founded in 1993

compugen ltd (CGEN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $295.8K
Vice President of Antibody Research & Develop...
Total Annual Compensation: $274.8K
Vice President of Research & Discovery
Total Annual Compensation: $193.6K
Vice President of R&D Planning and Control
Total Annual Compensation: $154.1K
Compensation as of Fiscal Year 2014.

compugen ltd (CGEN) Key Developments

Compugen Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for the Year 2015

Compugen Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. Revenues for the first quarter of 2015 were $0.5 million compared with $2.1 million in the comparable period of 2014. Net loss was $6.1 million, or $0.12 per diluted share, compared with a net loss of $1.9 million, or $0.04 per diluted share, in the comparable period of 2014. The significant increase in reported net loss for the first quarter of 2015 compared with the first quarter of 2014, largely relates to non-cash items such as the amortization of the upfront payment under the Bayer collaboration and the accounting treatment of the Baize agreement which was terminated in August 2014. Operating loss was $6.322 million compared with $3.311 million in the comparable period of 2014. Compugen previously estimated gross cash expenditures, to be in the range of $31 million to $33 million for the year 2015.

Compugen Ltd. to Report Q1, 2015 Results on May 05, 2015

Compugen Ltd. announced that they will report Q1, 2015 results at 10:00 AM, US Eastern Standard Time on May 05, 2015

Compugen Ltd., Q1 2015 Earnings Call, May 05, 2015

Compugen Ltd., Q1 2015 Earnings Call, May 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGEN:IT 2,486.00 0.00

CGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMPUGEN LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at